The chemokine receptor subtype CXCR4 is an attractive target for cancer diagnosis and treatment as it is overexpressed in more than 70% of human solid tumors, including mammary cancer, prostate cancer, B-cell lymphoma, neuroblastoma, melanoma, cervical adenocarcinoma, and glioma [1]. This evidence concerns the gene CXCR4 and breast cancer.